Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results

INTRODUCTION: iGlarLixi, the once-daily fixed-ratio combination of insulin glargine 100 U/ml and lixisenatide, robustly improves glycaemic control in adults with type 2 diabetes irrespective of previous treatment [oral antihyperglycaemic drugs (OADs), basal insulin or glucagon-like peptide-1 recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Guja, Cristian, Giorgino, Francesco, Blonde, Lawrence, Ali, Amar, Prázný, Martin, Meier, Juris J., Souhami, Elisabeth, Lubwama, Robert, Ji, Chen, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776928/
https://www.ncbi.nlm.nih.gov/pubmed/34894329
http://dx.doi.org/10.1007/s13300-021-01180-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776928/
https://www.ncbi.nlm.nih.gov/pubmed/34894329
http://dx.doi.org/10.1007/s13300-021-01180-1

Ejemplares similares